JCM
BMY.RT

Jacobi Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Jacobi Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,215
Closed -$3K – 1489
2020
Q4 		$3K Buy
4,215
+7
+0.2% +$15 ﹤0.01% 1137
2020
Q3 		$9K Sell
4,208
-200
-5% -$571 ﹤0.01% 842
2020
Q2 		$16K Hold
4,408
– – ﹤0.01% 692
2020
Q1 		$17K Buy
4,408
+10
+0.2% +$33 ﹤0.01% 617
2019
Q4 		$13K Buy
+4,398
New +$11.4K ﹤0.01% 714

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Jacobi Capital Management's BMY.RT Position: Q1 2021 in Review

Jacobi Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 4,215 shares — an estimated $3K sold.

Jacobi Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $17K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Jacobi Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 4,215 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3K.
  • Jacobi Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Jacobi Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $17K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Jacobi Capital Management's 13F filing for Q1 2021, filed 11 May 2021.